Lumos Pharma, an early stage biopharmaceutical development company, announced that it has raised According to a release, the round was co-led by
"We are extremely pleased to announce the closing of our Series A financing round from
Lumos Pharma noted its lead compound, LUM-001 has been granted orphan designation by the
"We are very grateful for the ongoing collaboration with TRND staff, and together with our new financial partners, Lumos is in an excellent position to succeed," says Hawkins. "TRND's dedication and contribution toward the development of therapies for rare diseases is nothing short of astounding."
Creatine Transporter Deficiency (CTD) is an inborn error of metabolism caused by a defect in the x-linked creatine transporter SLC6A8 gene, and falls within the general descriptive category of an Autism Spectrum Disorder. A defect in the SLC6A8 gene causes a defect in the transport of creatine across the blood-brain barrier, resulting in a near complete absence of cerebral creatine concentrations. The primary clinical manifestations of the disorder are x-linked mental retardation and global developmental delay, severe expressive speech and language delay, autistic behavior, and epilepsy. CTD is a completely unmet medical need. Patient registries are available.
Lumos Pharma is led by an experienced management team, including CEO
"Rick and his team have made terrific progress in the development of this promising new therapeutic agent over the last two years since we first started following the company," says Lalande. "
"We are delighted to be working with Rick, the Lumos team and our partners at
Lumos Pharma added it intends to immediately initiate the preclinical and clinical development of its lead compound with the goal of receiving marketing authorization from regulatory bodies worldwide.
((Comments on this story may be sent to email@example.com))
Lumos Pharma, an early stage biopharmaceutical development company, announced that it has raised
According to a release, the round was co-led by